Product Images Pregabalin

This is a description of a medication called GSMS in capsule form, with each capsule containing 25 mg of pregabalin. The text contains instructions for pharmacists to dispense the Medication Guide to patients and advises on storage conditions and dispensing in child-resistant containers. The medication should be stored at room temperature, and further details on dosage can be found in the accompanying Prescribing Information. The product is marketed by GSMS, Incorporated in Camarillo, CA.*

Each capsule contains 2250 mg pregabalin. Dosage and dispensing information can be found in the accompanying Prescribing Information. Store in child-resistant containers at a temperature between 15°C - 30°C (59°F - 86°F). Keep out of reach of children. This product is supplied in a pack with 90 capsules. Marketed by GSMS, Incorporated. Date of the revision: 07/24.*

This is a description of a medication called Pregabalin available in capsule form. Each capsule contains 75 mg of pregabalin. The text instructs pharmacists to provide a Medication Guide to each patient. It also includes dosage information and storage instructions. The medication is distributed by GSMS, Incorporated.*

This is information for Pregabalin Capsules containing 100 mg of pregabalin per capsule. The medication guide should be provided to each patient. These capsules come in a pack of 90 and they should be dispensed in child-resistant containers. The storage recommendation is at 25°C with excursions permitted up to 30°C. The medication is marketed by GSMS, Incorporated. For more details on dosage and prescribing information, refer to the accompanying document.*

This text provides details about Pregabalin capsules, each containing 150 mg of the active ingredient. It includes instructions for dispensing, storage conditions, and safety precautions. Patients are advised to be provided with a Medication Guide. The medication should be kept in child-resistant containers at temperatures between 15° - 30°C (59° - 86°F). The drug is distributed by GSMS, Incorporated in Camarillo, CA, USA. For dosage information, refer to the accompanying Prescribing Information.*

This is a product label for Pregabalin Capsules, each containing 200 mg of pregabalin. It includes dosage instructions, storage guidelines, and safety precautions, such as keeping the medication out of reach of children and dispensing in child-resistant containers. The label also provides information on where to access the Medication Guide online. Marketed by GSMS, Incorporated in Camarillo, CA, the capsules are available in a pack containing 90 capsules.*

This text is a label for Pregabalin capsules. It includes information about the medication, dosage, storage instructions, and the manufacturer's details. The capsules contain 225 mg of pregabalin each and should be dispensed in child-resistant containers. The text also reminds to keep the medication away from children and store it at the recommended temperature. Additionally, it instructs the pharmacist to provide the Medication Guide to each patient.*

This text is a medication label for ENS capsules containing 300 mg pregabalin. It includes information on dosage, storage instructions, and the requirement of dispensing the Medication Guide to patients by the pharmacist. The medication is to be kept in child-resistant containers and stored at room temperature. The capsules are made by GSMS, Incorporated in the USA.*

This text appears to show data related to the percent improvement in pain for patients taking Pregabalin 160 mg over a three-day period. The table indicates different percentages of improvement in pain compared to the baseline for various patients.*

This description mentions the improvement in pain levels from baseline for parent of patients who were given either Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, or Placsbo.*

This text appears to be a record of a study or experiment involving medications. The substances mentioned are "Pregabalin 100 mg three times a day", "Pregabalin 80 mg three times a day", and "Placebo". The data shows the number of patients improved over time and a percentage improvement in pain from baseline.*

The text provides information related to various dosage levels (50mg/day, 150mg/day, 300mg/day, 600mg/day) of a medication compared to a placebo. It indicates that there is statistical significance observed in comparison to the placebo.*

This text provides information on the percentage of patients improved with different doses of Pregabalin (300mg and 450mg) daily, as well as with a placebo. It also includes a graph showing the percentage improvement in pain from the baseline.*

This data appears to be a chart showing the estimated percentage of subjects without LTR (likely to return) between two groups (Progabain and Placebo) over a period of days. The percentages range from 100% to 0% for both groups over an unspecified time frame. The information seems to be related to a research or study comparing the effectiveness of Progabain versus Placebo on the return of subjects.*

This text provides information on the percentage of subjects improved after treatment with Pregabalin and Placebo over a 16-week period. The subjects are classified based on the degree of improvement, with numbers indicating the percentage of improvement from baseline to week 16. The data includes values ranging from 100 to 280, displayed in a table format for easy comparison.*

This text appears to show responder rates for different doses in a study. The responder rate at 40.6% is provided for some unidentified data points. Placebo doses of 2.5 mg/kg/day and 10 mg/kg/day are mentioned, with corresponding responder rates of 29.1% and 22.6%. The overall responder rate for the placebo group is not provided.*

This text provides formulas for calculating the CLCT (Cockcroft-Gault method) to estimate creatinine clearance in adults, based on age, weight, and serum creatinine levels. The formula for males is [140 - age (years)] x weight (kg) / 72 x serum creatinine (mg/dL), while for females, it is [140 - age (years)] x weight (kg) / 72 x serum creatinine (mg/dL) x 0.85. This calculation is essential for assessing kidney function in clinical settings.*